Sight Sciences (Nasdaq:SGHT) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SGHT Overzicht aandelen

Sight Sciences, Inc. is een oftalmologisch bedrijf dat medische apparatuur maakt en zich bezighoudt met de ontwikkeling en commercialisering van chirurgische en niet-chirurgische technologieën voor de behandeling van oogaandoeningen.

Over het bedrijf

SGHT fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 10.6% per jaar groeien

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Sight Sciences, Inc. Concurrenten

Pulmonx

NasdaqGS:LUNG

US$292.9m

ClearPoint Neuro

NasdaqCM:CLPT

US$298.3m

Treace Medical Concepts

NasdaqGS:TMCI

US$336.4m

Tactile Systems Technology

NasdaqGM:TCMD

US$342.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sight Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$6.18
52 Week Hoogtepunt	US$8.45
52 Week Laag	US$1.04
Bèta	2.72
11 maand verandering	-8.71%
3 maanden verandering	-0.16%
1 Jaar Verandering	73.60%
33 jaar verandering	-74.43%
5 jaar verandering	n/a
Verandering sinds IPO	-81.55%

Recent nieuws en updates

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Aug 15

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Jul 12

Recent updates

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Aug 15

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Jul 12

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 19

Analysts Have Been Trimming Their Sight Sciences, Inc. (NASDAQ:SGHT) Price Target After Its Latest Report

Mar 26

Rendement voor aandeelhouders

	SGHT	US Medical Equipment	US Markt
7D	-3.9%	-0.6%	-0.4%
1Y	73.6%	22.6%	34.1%

Rendement versus industrie: SGHT overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 22.3 % opleverde.

Rendement versus markt: SGHT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 33.4 %.

Prijsvolatiliteit

Is SGHT's price volatile compared to industry and market?
SGHT volatility
SGHT Average Weekly Movement	10.9%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SGHT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SGHT is het afgelopen jaar gedaald van 17% naar 11%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	214	Paul Badawi	www.sightsciences.com

Sight Sciences, Inc., een oogheelkundig bedrijf dat medische hulpmiddelen levert, houdt zich bezig met de ontwikkeling en commercialisering van chirurgische en niet-chirurgische technologieën voor de behandeling van oogziekten. Het bedrijf is actief in twee segmenten: chirurgisch glaucoom en droge ogen. Tot de producten van het bedrijf behoren OMNI Surgical System, een implantaatvrije glaucoomchirurgietechnologie die is geïndiceerd om de intraoculaire druk te verlagen bij volwassen patiënten met primair open-hoek glaucoom; en SION Surgical Instrument, een handmatig te bedienen apparaat dat wordt gebruikt bij oogchirurgische procedures om trabeculaire mazen te verwijderen.

Sight Sciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Sight Sciences zich tot de beurswaarde?
SGHT fundamentele statistieken
Marktkapitalisatie	US$304.86m
Inkomsten(TTM)	-US$52.32m
Inkomsten(TTM)	US$79.40m

3.9x

P/S-verhouding

-5.9x

Koers/Winstverhouding

Is SGHT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SGHT resultatenrekening (TTM)
Inkomsten	US$79.40m
Kosten van inkomsten	US$11.27m
Brutowinst	US$68.12m
Overige uitgaven	US$120.45m
Inkomsten	-US$52.32m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.04
Brutomarge	85.80%
Nettowinstmarge	-65.90%
Schuld/Eigen Vermogen Verhouding	33.2%

Hoe presteerde SGHT op de lange termijn?

Bekijk historische prestaties en vergelijking

SGHT Overzicht aandelen

Beloningen

Risicoanalyse

Sight Sciences, Inc. Concurrenten

NasdaqGS:LUNG

US$292.9m

NasdaqCM:CLPT

US$298.3m

NasdaqGS:TMCI

US$336.4m

NasdaqGM:TCMD

US$342.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target increased by 14% to US$7.38

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Narrows Earnings Guidance for the Full Year 2024

Sight Sciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Recent updates

Price target increased by 14% to US$7.38

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Narrows Earnings Guidance for the Full Year 2024

Sight Sciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Co-Founder recently sold US$81k worth of stock

Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma

CFO & Treasurer recently sold US$71k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Sight Sciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study

Co-Founder recently sold US$64k worth of stock

Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024

New minor risk - Insider selling

Sight Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting

Sight Sciences, Inc. announced that it expects to receive $65 million in funding

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Sight Sciences, Inc. Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Sight Sciences Announces the Acceptance for Publication of Gemini 2, A Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant Iop and Medication Reductions Enabled with the Omni® Surgical System Technology

Independent Chairman recently bought US$278k worth of stock

Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates

Price target decreased by 49% to US$3.13

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

New minor risk - Market cap size

Sight Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sight Sciences, Inc. Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Chief Operating Officer exercised options to buy US$130k worth of stock.

Sight Sciences, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 8.1% to US$10.48

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sight Sciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Sight Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 12% to US$12.80

Sight Sciences Announces Appointment of Catherine Mazzacco as New Director

Sight Sciences Two Year Multicenter Study Results Shows Sustained Reductions in Both Intraocular Pressure and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with A Procedure Enabled with the Omni Surgical System Technology

Sight Sciences, Inc. Announces 12-Month Results from the First Minimally Invasive Glaucoma Surgery

First quarter 2023 earnings: EPS exceeds analyst expectations

Sight Sciences Reaffirms Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Announces Executive Changes

Price target increased to US$14.60

Sight Sciences, Inc. Reports Improvements in Signs and Symptoms of Dry Eye Disease from A Single Tearcare

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Sight Sciences, Inc. Provides Revenue Guidance for Full Year 2022

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients